C4 Therapeutics, Inc.

Mark E Fitzgerald

Yanke Liang

Andrew John Phillips

Minsheng He

James A Henderson

Christopher G Nasveschuk

Ryan E Michael

Katrina L Jackson

Chris G Nasveschuk

Juergen Wichmann

Martin Duplessis

Cosimo Dolente

David Hewings

Piergiorgio Francesco Tommaso Pettazzoni

Daniela Krummenacher

Daniel Hunziker

Victoria Garza

The present invention provides compounds or their pharmaceutically acceptable salts and their pharmaceutical compositions that can be administered to a host such as a human in need thereof for the treatment of a disorder, such as cancer, mediated by mutant BRAF. The compounds efficiently degrade Class I, II and III mutant BRAF proteins.

Therapeutics for the degradation of mutant BRAF

This invention provides pharmaceutical protein degraders and E3 ubiquitin ligase binders for therapeutic applications as described further herein.

Targeted protein degradation

This invention provides heterocyclic compounds that bind to E3 Ubiquitin Ligase (typically through cereblon) ('Degrons'), which can be used as is or linked to a Targeting Ligand for a selected Target Protein for therapeutic purposes and methods of use and compositions thereof as well as methods for their preparation.

Heterocyclic degronimers for target protein degradation

Growing community of inventors

Watertown, MA, United States of America

Mark E Fitzgerald